**Specifications Table**TableSubject areaCardiologyMore specific subject areaAnticoagulation for atrial fibrillationType of dataTableHow data was acquiredAdministrative claims dataData formatAnalyzedExperimental factorsOLDW patients with atrial fibrillation receiving treatment with either warfarin, apixaban, dabigatran, or rivaroxabanExperimental featuresBaseline characteristics (age, gender, and CHADs2 score) and event rates (per 100 person years) for ischemic stroke or systemic embolism and major bleeding.Data source locationUS administrative claims, previously published international clinical trial dataData accessibilityIndividual, patient-level from Optum Labs Data Warehouse is not publically available, but summary data are provided in the tables and in the linked publication [@bib5] (DOI: [10.1016/j.ijcard.2017.07.043](http://10.1016/j.ijcard.2017.07.043){#ir0005a}). All clinical trial data included have been previously published.

**Value of the data**•These data can serve as a benchmark for 'real-world' outcomes in anticoagulated patients with atrial fibrillation.•These data may be valuable for comparison to outcomes and baseline characteristics observed in other dataset or in other countries.•These data describe potentially important differences in baseline characteristics between patients treated in routine practice and those enrolled in clinical trials.

1. Data {#s0005}
=======

These data are pulled from two sources: (1) a large administrative claims dataset including 107,373 anticoagulated patients with atrial fibrillation, and (2) the pivotal, phase III clinical trials that compared ear of the NOACs to warfarin (Granger et al., 2011; Cannolly et al., 2009; Patel et al., 2011; Giugliano et al., 2013) [@bib1], [@bib2], [@bib3], [@bib4]. Our data report illustrates baseline characteristics (age, gender, and CHADs2 score) as well as event rates for ischemic stroke or systemic embolism and major bleeding, overall and stratified by CHADS2 score.

1.1. Experimental design, materials and methods {#s0010}
-----------------------------------------------

Using a large U.S. administrative claims database, OptumLabs Data Warehouse (OLDW), which contains privately insured and Medicare Advantage enrollees of all ages and races from all 50 states, we identified adult patients (≥ 18 years) with AF who were new users of oral anticoagulants between July 1st, 2006 and June 30th, 2016, including warfarin, apixaban, dabigatran, or rivaroxaban. Because edoxaban was approved in 2015, there were insufficient sample size to report baseline characteristics and outcomes in edoxaban-treated patients in OLDW. We used the fill dates and days supplied per prescription to determine patients' treatment episodes. Patients were considered as continuing on treatment as long as they had another fill of the same medication within 90 days of the end of the last treatment episode. We required patients to have at least 12 months of continuous enrollment in health insurance, defined as the baseline, used to capture baseline characteristics. Patients were censored at the end of study period (i.e., 6/30/2016), discontinuation of the medication, switch to another oral anticoagulant, or the end of enrollment in health insurance, whichever occurred first.

The outcomes were inpatient admission for either stroke (effectiveness endpoint, including ischemic stroke and systemic embolism) or major bleeding (safety endpoint). When comparing outcomes to trials, we calculated the event rates per 100 years and stratified patients based on the CHADS2 score (a stroke risk score used in the trials). All the analyses were based on the time to the first event, an approach used in the trials. The study was exempt by the Mayo Clinic Institutional Review Board for approval as we used only pre-existing, de-identified data.
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